The page is the record's research on the issuer — no analyst, no rating, no view. # ADARx Pharmaceuticals, Inc. (NASDAQ: ADRX) — research page As of 2026-11-08 · us-cm-kg · record version 1 ## Identity and listing The issuer is ADARx Pharmaceuticals, Inc., listed on NASDAQ under ticker ADRX, with ISIN US00654F1057. The record holds no LEI, as no GLEIF record carries the exact legal name in jurisdiction US-DE. The security type is Non-operating entity type (other), the sector is 2834 Pharmaceutical Preparations, and the jurisdiction is United States, Delaware. The segment is not on the record. The issuer is listed and not halted. ## The disclosure read The record holds 40 filings in the twelve months from 2025-11-08 to 2026-11-08, across 14 filing days. Of these, 24 are directors' dealings, 10 are regulatory filings, 5 are prospectuses and 1 is corporate news. The median gap between filing days is 3 days. The latest filing is a regulatory filing dated 2026-10-16, 23 days before the record date of 2026-11-08. On NASDAQ the median cadence gap is 6.0 days, the median filings count is 52 and the median latency is 5.0 days across 4,359 issuers. In sector 2834 Pharmaceutical Preparations the median cadence gap is 6.0 days, the median filings count is 63.0 and the median latency is 4.0 days across 526 issuers. ## Auditor The auditor of record is not on the record, because the latest annual report cover carries no dei:AuditorName tag. The auditor's location is not on the record. The record holds no auditor changes. ## Events and halts The record holds two listing lines, dated 2026-09-22 and 2026-09-24. It holds no delisting and no name change. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The issuer is listed and not halted. ## Orderability The outcome is not determinable, because the chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04. ## Coverage No research houses were found on the investor-relations pages read, and the count is 0. ## Open research No openly published research notes were found, and the count is 0. ## Licensed Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded. ## As-of depth The sealed years that hold the issuer are 2021, 2023 and 2026. The market's vintage is sealed, with the earliest sealed date being 2021-01-04. The live record began on 2026-09-12. ## Sources 7 source pages are named on this page; every value above carries its own source page and read date in the numbers. - https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange) - https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin) - https://data.sec.gov/submissions/CIK0001802369.json (identity.jurisdiction) - https://mcp.us-cm-kg.ai/events/NASDAQ/ADRX (the disclosure lines) - https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag) - https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter) - https://mcp.us-cm-kg.ai/record/NASDAQ/ADRX (the record) --- Allooloo Technologies Corp. · https://getresearch.ai/us/NASDAQ/ADRX · public-record only · the same page signed and receipted: get_research at https://mcp.getresearch.ai/mcp